Equities Analysts Set Expectations for Stryker Corporation’s Q2 2018 Earnings (SYK)

Stryker Corporation (NYSE:SYK) – Research analysts at Northcoast Research decreased their Q2 2018 earnings per share (EPS) estimates for Stryker in a report issued on Friday, according to Zacks Investment Research. Northcoast Research analyst D. Keiser now forecasts that the medical technology company will post earnings of $1.68 per share for the quarter, down from their prior estimate of $1.69.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.01. The firm had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.52%. The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the company earned $1.78 earnings per share.

Several other research firms also recently weighed in on SYK. SunTrust Banks reiterated a “buy” rating and issued a $179.00 target price (up previously from $161.00) on shares of Stryker in a research note on Friday, January 26th. Cantor Fitzgerald reiterated a “hold” rating and issued a $163.00 target price on shares of Stryker in a research note on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research note on Wednesday. Leerink Swann lifted their target price on shares of Stryker from $177.00 to $184.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Oppenheimer reiterated a “hold” rating and issued a $165.00 target price on shares of Stryker in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $162.50.

Stryker (NYSE SYK) traded up $0.43 on Monday, hitting $164.78. 1,500,000 shares of the stock traded hands, compared to its average volume of 1,200,000. The stock has a market capitalization of $61,670.00, a P/E ratio of 61.49, a price-to-earnings-growth ratio of 2.41 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. Stryker has a 52-week low of $121.86 and a 52-week high of $170.00.

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 1.14%. Stryker’s payout ratio is presently 70.15%.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Securities Group LLC bought a new stake in shares of Stryker in the 4th quarter worth approximately $511,000. Hendley & Co. Inc. lifted its holdings in shares of Stryker by 10.3% in the 4th quarter. Hendley & Co. Inc. now owns 5,333 shares of the medical technology company’s stock worth $826,000 after acquiring an additional 500 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Stryker by 8.9% in the 4th quarter. Victory Capital Management Inc. now owns 26,252 shares of the medical technology company’s stock worth $4,065,000 after acquiring an additional 2,138 shares during the last quarter. Harrington Investments INC lifted its holdings in shares of Stryker by 9.3% in the 4th quarter. Harrington Investments INC now owns 8,954 shares of the medical technology company’s stock worth $1,386,000 after acquiring an additional 760 shares during the last quarter. Finally, CIBC World Markets Inc. lifted its holdings in shares of Stryker by 17.1% in the 4th quarter. CIBC World Markets Inc. now owns 22,193 shares of the medical technology company’s stock worth $3,436,000 after acquiring an additional 3,241 shares during the last quarter. Hedge funds and other institutional investors own 74.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/02/northcoast-research-comments-on-stryker-corporations-q2-2018-earnings-syk.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply